In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced ...
Researchers say a new AI system can identify disease-causing mutations and explain their biological effects, potentially ...
A new agentic AI application aims to speed up drug development, helping bring new medical treatments to patients faster.
In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell ...
Former Sen. Ben Sasse gives a glimpse of what it's like to be a participant in an tough but promising new drug for pancreatic ...
Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...
Unprecedented,” “remarkable” and “transformative” were just a few of the descriptives tossed out by Wall Street analysts in response to Revolution Medicines Inc.’s phase III readout, showing RAS ...
At the 2026 ASCRS Annual Meeting in Washington, DC, several presentations converged on a set of questions that define the ...
The global rise in the prevalence of obesity highlights the need for accessible and effective solutions for obesity ...
Introduction In cluster randomised trials (CRT), groups (rather than individuals) are randomised to intervention and control conditions. Since the publication of the Ottawa Statement on the Ethical ...
Patients with traumatic brain injury who used a pair of virtual reality programs experienced improvements in prospective ...
Before the study begins at Long Beach Medical Center, participation requires engaging in community outreach to provide information, answer questions, and gather public input about this important ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results